This cluster groups 2 independently calculated changes: Cash & equivalents decreased 47.9%; Operating cash flow decreased 11.2%.
2 evidence-backed components· Surgical & Medical Instruments & Apparatus
RESEARCH SNAPSHOTModular Medical, Inc.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 47.9%; Operating cash flow decreased 11.2%.
2 evidence-backed componentsStock-based compensation changed -38.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
MODD · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-097280SEC ↗10-QAug 14, 2026Period Jun 30, 20260001213900-26-090301SEC ↗4Jul 2, 2026Period Jun 30, 20260001213900-26-075026SEC ↗4Jul 2, 2026Period Jun 30, 20260001213900-26-075025SEC ↗4Jul 2, 2026Period Jun 30, 20260001213900-26-075023SEC ↗4Jul 2, 2026Period Jun 30, 20260001213900-26-075022SEC ↗4Jul 2, 2026Period Jun 30, 20260001213900-26-075011SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 30, 2026Filed Jul 2, 2026 | Vos Ellen O'ConnorDirector | Grant Or AwardDirect | 250 | — | — | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Capital expenditure changed -26.3% from the comparable as-filed period. The change ranks at the 14th percentile of 7 prior comparable changes. This reverses 7 consecutive comparable moves in the opposite direction.
Cash & equivalents changed -47.9% from the comparable as-filed period.
Operating income changed +3.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Operating cash flow changed -11.2% from the comparable as-filed period. The change ranks at the 29th percentile of 7 prior comparable changes.
Research & development changed -14.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Free-cash-flow proxy changed -5.6% from the comparable as-filed period. The change ranks at the 0th percentile of 7 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001213900-26-075017